Schizophrenia News

Results presented in a poster at the U.S. Psychiatric and Mental Health Congress indicate no significant differences in health care utilization and total costs between paliperidone palmitate monotherapy and adjunctive therapy for individuals with schizoaffective disorder.

The FDA today approved Vraylar to treat schizophrenia and bipolar disorder in adults, according to a press release.

SAN DIEGO — Nonadherence to antipsychotic medication and substance misuse may be more common among individuals with major depressive disorder or bipolar disorder than among those with schizophrenia, according to data presented at U.S. Psychiatric and Mental Health Congress.

The FDA is altering requirements for monitoring, prescribing, dispensing and receiving clozapine to address continued safety concerns about severe neutropenia.

The goals of schizophrenia treatment are manifold and include improving the patient’s ability to function, preventing treatment failure and reducing negative symptoms.

A single dose of cocaine may impair an individual’s ability to recognize negative emotions such as sadness and anger, according to data presented at the 25th Annual European College of Neuropsychopharmacology Congress.

Researchers from Canada found that small gestational age and preterm birth significantly predicted the risk of developing schizophrenia in patients with 22q11.2 deletion syndrome, according to recent study results published in Genetics in Medicine.

Negative symptoms of schizophrenia — withdrawal, lack of emotion and apathy — may be treatable with cariprazine, according to results from a phase 3 clinical trial presented at the European College of Neuropsychopharmacology Congress annual meeting.

Individual differences in striatal functional connectivity predicted response to antipsychotic treatment among individuals with acute psychotic illness, according to study findings in the American Journal of Psychiatry.

Results from a prospective, register-based cohort study indicate that individuals with severe mental illness who also have a substance use disorder have higher mortality compared with their peers without substance use disorders.